Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia.

The aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least 12 months since diagnosis

• Insulin naive subjects

• OAD treatment for at least 4 months with max. two OAD treatments

• Body mass index below 30.0 kg/m2

• HbA1c between 7.0-11.0%

Exclusion Criteria:

• OAD treatment with three or more OADs

• Secondary diabetes

• Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator

• Uncontrolled hypertension

• Known or suspected allergy to trial product or related products